Venus Remedies News and Updates

Keep track of all breaking news on Venus Remedies from all sources in a single place.

24 May 2025

762.90

2.40%

Venus Remedies gets GMP renewal certification from Ukraine's SMDC

Business Standard

Pharma major Venus Remedies on Saturday said it has successfully renewed its good manufacturing practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement. "Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said. Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 .

Venus Remedies has gained 10.38% in the last 1 Week

Venus Remedies Ltd.

17 Apr 2025

762.90

2.40%

Venus Remedies shares climb 14% after US FDA grants QIDP status to VRP-034

Business Standard

The company's investigational product, VRP-034, has been granted QIDP designation by the US FDA for the treatment of bloodstream infections caused by polymyxin B (PMB)-susceptible strains in adults

Venus Remedies has gained 70.94% in the last 1 Month

Venus Remedies Ltd.

25 Feb 2025

762.90

2.40%

Venus Remedies to co-develop antibiotic resistance blocker with UK firm

Business Standard

Clinical trials to start next year, and drug can be in market by 2031-32

Venus Remedies has gained 66.08% in the last 3 Months

Venus Remedies Ltd.

25 Feb 2025

762.90

2.40%

Venus Remedies up 4% after entering license agreement with UK-based Infex

Business Standard

The agreement authorises Venus Remedies to spearhead the clinical development, registration, and commercialisation of MET-X, an innovative metallo-beta- lactamase (MBL) inhibitor